Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Chezi Ganzel, Larry D. Cripe, MD, Zhouxin Sun, Hugo F. Fernandez, MD, Peter A Cassileth, MD, Dan Douer, MD, Jacob M. Rowe, MD, Elisabeth Paietta, PhD, Michael O'Connell, Peter H Wiernik, John M. Bennett, MD, Mark R Litzow, MD, Selina Luger, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1315.

https://doi.org/10.1182/blood.V126.23.1315.1315

Published: 2015

Journal Articles

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Chezi Ganzel, MD, Judith Manola, MS, Dan Douer, MD, Jacob M. Rowe, MD, Hugo F Fernandez, MD, Elisabeth Paietta, Ph.D, Mark R. Litzow, MD, Ju-Whei Lee, Selina M Luger, MD, Hillard M. Lazarus, MD, Larry Cripe, MD, Martin M Oken, MD, Peter A Cassileth, MD, Martin S. Tallman, MD

Blood (2013) 122 (21): 63.

https://doi.org/10.1182/blood.V122.21.63.63

Published: 2013

Journal Articles

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Ranjana H. Advani, MD, Hailun Li, MS, Richard T. Hoppe, MD, Nancy L. Bartlett, MD, John M. Bennett, MD, Donna S. Neuberg, ScD, Peter A Cassileth, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 4779.

https://doi.org/10.1182/blood.V120.21.4779.4779

Published: 2012

Journal Articles

Practically All Patients with Acute Myeloid Leukemia (AML) in Continuous Complete Remission for 3 Years or More Are Cured of Their Disease: The ECOG Experience

Justin M Watts, MD, Lynette Zickl, MS, Mark R Litzow, MD, Selina M Luger, MD, Hillard M Lazarus, MD, Peter A Cassileth, MD, Hugo F Fernandez, MD, Dan Douer, MD, Elisabeth Paietta, PhD, Jacob M Rowe, MD, Martin S Tallman, MD

Blood (2012) 120 (21): 132.

https://doi.org/10.1182/blood.V120.21.132.132

Published: 2012

Journal Articles

Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

Jacob M. Rowe, MD, Zhuoxin Sun, Ph.D, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Karl G. Blume, MD, Hugo F. Fernandez, MD, Mark R. Litzow, MD, Martin S Tallman

Blood (2008) 112 (11): 49.

https://doi.org/10.1182/blood.V112.11.49.49

Published: 2008

Journal Articles

The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).

Jacob M. Rowe, MD, Xiaopan Yao, Ph.D, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Peter H. Wiernik, MD, Charles Schiffer, MD, Mark R. Litzow, MD, Selina Luger, MD, John M. Bennett, MD, Hillard M Lazarus, MD, Martin S Tallman

Blood (2008) 112 (11): 1952.

https://doi.org/10.1182/blood.V112.11.1952.1952

Published: 2008

Journal Articles

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Jacob M. Rowe, MD, Xiaochun Li, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Charles A. Schiffer, MD, Peter H. Wiernik, MD, Mark R. Litzow, MD, Larry D. Cripe, MD, Hillard M. Lazarus, MD, Elisabeth Paietta, Ph.D, Gordon W. Dewald, MD, Howard J. Weinstein, MD, Angela K. Ogden, MD, William G. Woods, MD, Lois Shepherd, MD, James H. Feusner, MD, Clara D. Bloomfield, MD, Martin S. Tallman, MD

Blood (2005) 106 (11): 546.

https://doi.org/10.1182/blood.V106.11.546.546

Published: 2005

Journal Articles

Time To Complete Remission Is Not a Significant Prognostic Factor in AML: A Report on 1,959 Consecutive Patients Registered to 6 Studies of the Eastern Cooperative Oncology Group (ECOG).

Jacob M. Rowe, MD, Haesook T. Kim, PhD, Peter A. Cassileth, MD, Mark R. Litzow, MD, Peter H. Wiernik, MD, Martin S. Tallman, MD

Blood (2004) 104 (11): 862.

https://doi.org/10.1182/blood.V104.11.862.862

Published: 2004

Journal Articles

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

Marilyn L. Slovak, Kenneth J. Kopecky, Peter A. Cassileth, David H. Harrington, Karl S. Theil, Anwar Mohamed, Elizabeth Paietta, Cheryl L. Willman, David R. Head, Jacob M. Rowe, Stephen J. Forman, Frederick R. Appelbaum

Blood (2000) 96 (13): 4075–4083.

https://doi.org/10.1182/blood.V96.13.4075

Published: 2000

Journal Articles

Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience: Presented in part at the American Society of Hematology meeting, New Orleans, LA, December 1999.

Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J. Francois, Elisabeth Paietta, Peter H. Wiernik, Gordon Dewald, Peter A. Cassileth, Martin M. Oken, Jacob M. Rowe

Blood (2000) 96 (7): 2405–2411.

https://doi.org/10.1182/blood.V96.7.2405

Published: 2000

Journal Articles

A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose Intensity

Leo I. Gordon, Mary Young, Edie Weller, Thomas M. Habermann, Jane N. Winter, John Glick, Chirantan Ghosh, Patrick Flynn, Peter A. Cassileth

Blood (1999) 94 (10): 3307–3314.

https://doi.org/10.1182/blood.V94.10.3307.422k11_3307_3314

Published: 1999

NARROW

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Practically All Patients with Acute Myeloid Leukemia (AML) in Continuous Complete Remission for 3 Years or More Are Cured of Their Disease: The ECOG Experience

Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Time To Complete Remission Is Not a Significant Prognostic Factor in AML: A Report on 1,959 Consecutive Patients Registered to 6 Studies of the Eastern Cooperative Oncology Group (ECOG).

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience: Presented in part at the American Society of Hematology meeting, New Orleans, LA, December 1999.

A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose Intensity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only